anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systemic Immune Inflammatory Index (SII) is a novel indicator of inflammation. However, no studies have reported the effect of SII on the association between metals and total fat (TOFAT). We aim to investigate the mediated effect of SII on the relationship between urinary metals and TOFAT in a US adult population. This cross-sectional study was conducted among adults with complete information on SII, urine metal concentrations, and TOFAT from the 2011-2018 National Health and Nutrition Examination Survey (NHANES). Multifactorial logistic regression and restricted cubic splines were used to explore the association between urine metal levels and TOFAT. Furthermore, serial mediation analyses were used to investigate the mediating effect of SII on metals and TOFAT. A total of 3324 subjects were included in this study. After adjusting for confounders, arsenic (As), cadmium (Cd), cobalt (Co), cesium (Cs), inorganic mercury (Hg), molybdenum (Mo), manganese (Mn), lead (Pb), antimony (Sb), and thallium(Tl) had negative decreased trends of odds ratios for TOFAT (all P for trend < 0.05). In the total population, we found that Cd, Co, and Tu were positively associated with SII (β = 29.70, 79.37, and 31.08), whereas As and Hg had a negative association with SII. The mediation analysis showed that SII mediated the association of Co with TOFAT, with the β of the mediating effect being 0.9% (95%CI: 0.3%, 1.6%). Our findings suggested that exposure to As, Cd, and Hg would directly decrease the level of TOFAT. However, Co would increase TOFAT, completely mediated by SII, mainly exerted in females rather than males.
PURPOSE: To provide a treating tool for periodontosis, enabling a therapeutic medicine for periodontosis to manifest effects thereof for a long period and expectable of high therapeutic effects. CONSTITUTION: This treating tool for periodontosis is obtained by impregnating a molding, made of a resin and having a mouthpiecelike structure, with a therapeutic medicine for the periodontosis and devising the tool so as to sustainedly release the therapeutic medicine for a long period. The therapeutic medicine is released according to the digestion of a substrate (e.g. starch) in the molding with saliva or by application of the therapeutic medicine together with an ingredient dissolving the therapeutic medicine into the molding and diffusion of the ingredient dissolving the therapeutic medicine into the mouth with the saliva. The therapeutic medicine is released from the tool having the mouthpiecelike structure wrapping teeth for a long period to sustainedly reach the gingiva and provide high therapeutic effects.  The treating tool is conveniently used during sleep and the treatment can be carried out while a patient stays in bed.
The present invention relates to a substrate for use in a transdermal patch or 5 dressing, such as a wound dressing. The substrate includes an absorbent matrix loaded with ceramic particles that encapsulate a releasable dopant. Methods for loading such ceramic particles into substates and forming transdermal patches and dressings are also provided. The present invention relates to a substrate for use in a transdermal patch or dressing, such as a wound dressing. The substrate includes an absorbent matrix loaded with ceramic particles that encapsulate a releasable dopant. Methods for loading such ceramic particles into substates and forming transdermal patches and dressings are also provided.
PURPOSE:To obtain the titled agent exhibiting extremely excellent 5- lipoxygenase inhibiting activity and useful as a remedy for asthma, an immunoactivating agent, etc., by using a kinic acid caffeic acid ester or kinic acid caffeic sinapic acid ester as an active component. CONSTITUTION:Caffeic acid ester of kinic acid or caffeic sinapic acid ester of kinic acid is used as an active component of the objective agent. It can be used as an agent for oral administration (e.g. tablet or capsule) or for parenteral administration (e.g. injection or drops). The kinic acid ester used as an active component is e.g. 3-O-caffeoyl-4-O-sinapoyl kinate [extracted and separated from SANSHISHI (Gardenia jasminoides) which is a herb growing in China, etc.] and 3,5-O-dicaffeoyl kinate (extracted and separated from coffee beans).
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross GI blood loss, fluid retention, or an incompletely described effect upon erythropoiesis. If a patient treated with COMBOGESIC has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. 

NSAIDs, including the ibuprofen in COMBOGESIC, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].
Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
Patients with intermittent claudication have decreased functional abilities and impaired quality of life \[QOL\]. In addition, peripheral arterial disease is associated with an increased risk of a life threatening cardiovascular event. Due to advances in endovascular technologies, peripheral revascularization procedures are now offered to a growing number of patients with lifestyle limiting claudication, rather than solely for the treatment of critical limb ischemia. Indeed, according to data derived from the National Health Discharge Survey, there was a 979% increase in the number of catheter-based revascularization procedures performed during the period 1995-2000. Despite well defined patency outcomes, the functional and QOL benefits of catheter-based revascularization procedures are largely undefined. In addition to improving leg symptoms and QOL, increasing walking ability among patients with claudication may lead to a less sedentary lifestyle and improvement of the cardiovascular risk factor profile. However, this relationship has not yet been demonstrated. The proposed project is a longitudinal cohort study that will follow patients with intermittent claudication for one year after a catheter-based revascularization procedure to measure changes in functional capacity, QOL, and cardiovascular risk factors. Patients will be evaluated at baseline and at 3 and 12 months following the procedure. A total of 60 patients will be studied over a three-year period. Functional parameters to be assessed will include treadmill walking distances, the 6-minute walk test, walking velocity, and self-assessed walking ability as determined by the Walking Impairment Questionnaire. Activity level during daily life will be assessed using a vertical accelerometer device, which will be worn by patients for a 7-day period at each time point. Quality of life will be assessed by the Short Form-36 Questionnaire and the Geriatric Depression Scale. Cardiovascular risk factors to be measured will include anthropomorphic parameters, blood pressure, lipids, markers of inflammation, homocysteine, and insulin-sensitivity. It is intended that data generated from this study will provide initial data to plan a multi-centered randomized clinical trial of best medical therapy and exercise training versus catheter-based revascularization for the treatment of lifestyle limiting claudication.
Surgeons have been reluctant to perform crossed-pin fixation for displaced pediatric supracondylar humeral (SCH) fractures because it carries a risk of iatrogenic ulnar nerve injury. This study aimed to introduce lateral-exit crossed-pin fixation for displaced pediatric SCH fractures and to evaluate its clinical and radiological outcomes, with a particular focus on iatrogenic ulnar nerve injuries. Children who underwent lateral-exit crossed-pin fixation for displaced SCH fractures between 2010 and 2015 were retrospectively reviewed. Lateral-exit crossed-pin fixation involved the introduction of a medial pin from the medial epicondyle, as in the conventional method, followed by pulling the pin through the lateral skin until the distal and medial aspects of the pin were just under the cortex of the medial epicondyle. The time to union and loss of fixation were assessed. Flynn's clinical criteria (cosmetic and functional factors) and complications including iatrogenic ulnar nerve injury were investigated. A total of 81 children with displaced SCH fractures were treated with lateral-exit crossed-pin fixation. All but one patient achieved union with good alignment, with an average time to union of 7.9 weeks (3.9-10.3 weeks). Only one patient exhibited cubitus varus deformity associated with loss of reduction. All patients recovered to almost their full range of motion. No case of iatrogenic ulnar nerve injury developed; however, iatrogenic radial nerve injury developed in one patient. Lateral-exit crossed-pin fixation provides sufficient stability with a lower risk of iatrogenic ulnar nerve injury in children with displaced SCH fractures. This method is an acceptable technique for crossed-pin fixation.
LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
BACKGROUND: Nowadays, large benign lateral spreading lesions (LSLs) and sessile polyps in the colorectum are mostly resected by endoscopic mucosal resection (EMR). A major drawback of EMR is the polyp recurrence rate of up to 20%. Snare tip soft coagulation (STSC) is considered an effective technique to reduce recurrence rates. However, clinical trials on STSC have mainly been conducted in expert referral centers. In these studies, polyp recurrence was assessed optically, and additional adjunctive techniques were excluded. In the current trial, we will evaluate the efficacy and safety of STSC in daily practice, by allowing adjunctive techniques during EMR and the use of both optical and histological polyp recurrence to assess recurrences during follow-up.
METHODS: The RESPECT study is a multicenter, parallel-group, international single blinded randomized controlled superiority trial performed in the Netherlands and Germany. A total of 306 patients undergoing piecemeal EMR for LSLs or sessile colorectal polyps sized 20-60 mm will be randomized during the procedure after endoscopic complete polyp resection to the intervention or control group. Post-EMR defects allocated to the intervention group will be treated with thermal ablation with STSC of the entire resection margin. Primary outcome will be polyp recurrence by optical and histological confirmation at the first surveillance colonoscopy after 6 months. Secondary outcomes include technical success and complication rates.
DISCUSSION: The RESPECT study will evaluate if STSC is effective in reducing recurrence rates after piecemeal EMR of large colorectal lesions in daily clinical practice performed by expert and non-expert endoscopists. Moreover, endoscopists will be allowed to use adjunctive techniques to remove remaining adenomatous tissue during the procedure. Finally, adenomatous polyp recurrence during follow-up will be defined by histologic identification.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05121805. Registered on 16 November 2021. Start recruitment: 17 March 2022. Planned completion of recruitment: 31 April 2025.
PURPOSE: To obtain a suspension liquid formulation, capable of suppressing the liberation of ibuprofen, freed of or reduced in irritancy and bitterness in administration and useful for producing a salycylic acid-based antipyretic and analgesic agent. CONSTITUTION: This ibuprofen suspension liquid formulation is obtained by adding and completely dissolving a preservative and a sweetener in an aqueous solution (pH 2.0-5.0) containing a pH adjustor such as a citric acid buffer solution dissolved therein, adding and uniformly dispersing a surfactant (sucrose esters of fatty acids), a porous inorganic thickening agent (synthetic aluminum silicate, etc.) and other thickening agents (xanthan gum, etc.) therein, then aging and dispersing ibuprofen, a salicylic acid-based analgesic agent (ethenzamide, etc.), regulating the total amount to 100wt.% with purified water and subsequently heat-treating the dispersion at 55-65 deg.C for 10-20min. The range of pH of the resultant suspension liquid formulation is preferably 2.5-4.0.  The respective amounts of the mixture in reaction are preferably 10-80wt.% inorganic thickening agent and 0.0025-2wt.% surfactant.
Current guidelines for referring cystic fibrosis (CF) patients for lung transplantation, based on clinical and functional resting parameters, are insufficient to predict 3-year mortality. Previous studies have shown that sex, impaired pulmonary function, undernutrition and colonization of the respiratory tract by Pseudomonas aeruginosa are associated with a poor prognosis. Current guidelines for referral to a lung transplant center include age, sex, forced expiratory volume at one second (FEV1) below 30% predicted or a rapid decline of FEV1, in particular in young female patients, increasing frequency of exacerbations requiring antibiotic therapy, refractory or recurrent pneumothorax, recurrent hemoptysis not controlled by embolization. But, despite these criteria, near that 30% of patients are still dying while on the lung transplant waiting list, or are transplanted in high emergency. Cardiopulmonary exercise testing (CPET) in CF patients would have an interest in the following of cystic fibrosis patients. A previous study, carried out on fifty one adult patients, showed that CPET with blood gas analysis may have a prognosis value in cystic fibrosis. The authors found that a BMI \< 19.8 and P(A-a)O2 peak \> 43 mmHg were independently associated with a lower chance of survival.
There have been no adequate and well-controlled studies of amphotericin B liposome for injection in pregnant women. Systemic fungal infections have been successfully treated in pregnant women with amphotericin B deoxycholate, but the number of cases reported has been small.  
  
Segment II studies in both rats and rabbits have concluded that amphotericin B liposome for injection had no teratogenic potential in these species. In rats, the maternal non-toxic dose of amphotericin B liposome for injection was estimated to be 5 mg/kg (equivalent to 0.16 to 0.8 times the recommended human clinical dose range of 1 to 5 mg/kg) and in rabbits, 3 mg/kg (equivalent to 0.2 to 1 times the recommended human clinical dose range), based on body surface area correction. Rabbits receiving the higher doses, (equivalent to 0.5 to 2 times the recommended human dose) of amphotericin B liposome for injection experienced a higher rate of spontaneous abortions than did the control groups. Amphotericin B liposome for injection should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks involved.
BACKGROUND: Previous studies have demonstrated that sarcopenia was associated with a high risk of cardiovascular disease (CVD). Nevertheless, little is known about the associations between sarcopenic obesity/possibly sarcopenic obesity and the risk of CVD among senior and middle-aged adults.
METHODS: Utilizing the nationally representative data from the China Health and Retirement Longitudinal Study (CHARLS), a sum of 7703 individuals aged at least 45 years were divided into four groups. The effects of sarcopenic obesity and possibly sarcopenic obesity on CVD were calculated using Cox proportional hazards regression models. Non-sarcopenic participants with optimal body mass index (BMI) or waist circumference (WC) served as a control group.
RESULTS: Sarcopenic obesity were related to increased risks of CVD (HR = 1.39; 95% CI = 1.16-1.67), heart disease (HR = 1.36; 95% CI = 1.10-1.67) and stroke (HR = 1.40; 95% CI = 1.02-1.92) compared with the optimal reference group. Similarly, the risk of CVD, heart disease and stroke increased by 0.34, 0.28 and 0.39 times in obese people with possible sarcopenia compared to the control group. Sensitivity analysis identified similar results to those described above. Patients with sarcopenia and a BMI ≥28.0 kg/m2 had a 1.47- and 1.48-fold risk of developing CVD and heart disease than controls.
CONCLUSION: Sarcopenic obesity and possibly sarcopenic obesity are positively associated with the development of CVD. The middle-aged and elderly population should prevent obesity and maintain muscle mass through some interventions such as weight control and moderate exercise, which may reduce the CVD risk.
Osteoporosis is a growing problem worldwide, with the greatest burden resulting from fractures. Nevertheless, the majority of fractures in adults occur in those with "osteopenia" (bone mineral density (BMD) only moderately lower than young normal individuals) Since life long drug therapy is an expensive option with uncertain consequences and side effect, natural herbal therapy offers an attractive alternative. The classic Yin and Yang Tonic Formula (eg.Zuogui Pill, Yougui Pill) have been used for osteoporosis or osteopenia in traditional Chinese medicine(TCM) for a long time. For this reason, Chinese guidelines for the treatment of osteopenia include natural herbal therapy, however, there is currently no randomize placebo controlled trial to verify the efficacy for treating low BMD. This trial is randomized, double blind, placebo controlled design. Results of this study will provide evidence regarding the value of the classic Yin and Yang tonic formula as an intervention for increase BMD and decreasing fracture risk in osteopenia. Furthermore, the mechanisms of action can be identified by this study.
If participants do not test positive for MRD, you will be enrolled in Group 2. Participants in this group will only receive ASTX727. If participants are enrolled in Group 2, the participant will take ASTX727 on Days 1-3 of each cycle.
IPF is a chronic, progressive, interstitial lung disease with high mortality. Current drugs have limited efficacy in curbing disease progression and improving quality of life. Selpercatinib, a highly selective inhibitor of receptor tyrosine kinase RET (rearranged during transfection), was approved in 2020 for the treatment of a variety of solid tumors with RET mutations. In this study, the action and mechanism of Selpercatinib in pulmonary fibrosis were evaluated in vivo and in vitro. In vivo experiments demonstrated that Selpercatinib significantly ameliorated bleomycin (BLM)-induced pulmonary fibrosis in mice. In vitro, Selpercatinib inhibited the proliferation, migration, activation and extracellular matrix deposition of fibroblasts by inhibiting TGF-β1/Smad and TGF-β1/non-Smad pathway, and suppressed epithelial-mesenchymal transition (EMT) like process of lung epithelial cells via inhibiting TGF-β1/Smad pathway. The results of in vivo pharmacological tests corroborated the results obtained from the in vitro experiments. Further studies revealed that Selpercatinib inhibited abnormal phenotypes of lung fibroblasts and epithelial cells in part by regulating its target RET. In short, Selpercatinib inhibited the activation of fibroblasts and EMT-like process of lung epithelial cells by inhibiting TGF-β1/Smad and TGF-β1/non-Smad pathways, thus alleviating BLM-induced pulmonary fibrosis in mice.
The present invention aims to provide a red rice and ginkgo leaf composition for preventing or treating cardiovascular and cerebrovascular diseases according to the defects of the existing medicines for preventing and treating cardiovascular and cerebrovascular diseases. The composition can effectively and safely prevent or treat cardiovascular and cerebrovascular diseases. The present invention also relates to the application of the composition to the aspects of health-care products or food additives. The composition is prepared from the effective components of a proportion by weight: 1 to 5 of red rice and 1 to 5 of ginkgo leaf on a dry substance basis. The composition can be applied to health-care food or food additives, and has certain health-care effect on human bodies. The present invention broadly and deeply researches components with the functions of reducing blood lipid and preventing and treating cardiovascular and cerebrovascular diseases in the red rice and the ginkgo leaves. Research proves that all components of the composition of red rice, or red rice extract and ginkgo leaves or ginkgo leaf extract are prepared according to a certain proportion relationship, so the components have significant synergistic effect. The components are not simply combined.
Abstract The disclosure provides dosing regimens and methods for treating atherosclerosis with an effective amount of Apo E mimetic to provide sustained therapeutic effects even after withdrawal of the treatment. The dosing regimens and methods involve a treatment cycle followed by a rest phase wherein a subject is administered an effective amount of an Apo E mimetic during the treatment cycle and no Apo E mimetic during the rest phase. The treatment cycle and the rest phase can vary. GIKKFLGSIWKFIKAFVG Ac-GFKKFLGSWAKIYKAFVG-NH 2 I8L mI8L Ac-GFRRFLGSWARIYRAFVG-NH 2 FiG. 1A, FIG. IB, and FIG. 1C mRI8L
BACKGROUND: Liposomal bupivacaine is reported to prolong the duration of analgesia when used for abdominal fascial plane blocks compared to plain local anesthetics; however, evidence from randomized trials is mixed. This meta-analysis aims to compare the analgesic effectiveness of liposomal bupivacaine to plain local anesthetics in adults receiving abdominal fascial plane blocks.
METHODS: Randomized trials comparing liposomal bupivacaine and plain (nonliposomal) local anesthetics in abdominal fascial plane blocks were sought. The primary outcome was area under the curve rest pain between 24 to 72 h postoperatively. Secondary outcomes included rest pain at individual timepoints (1, 6, 12, 24, 48, and 72 h); analgesic consumption at 0 to 24, 25 to 48, and 49 to 72 h; time to analgesic request; hospital stay duration; and opioid-related side effects. Data were pooled using the Hartung-Knapp-Sidik-Jonkman random effects method.
RESULTS: Sixteen trials encompassing 1,287 patients (liposomal bupivacaine, 667; plain local anesthetics, 620) were included. The liposomal bupivacaine group received liposomal bupivacaine mixed with plain bupivacaine in 10 studies, liposomal bupivacaine alone in 5 studies, and both preparations in 1 three-armed study. No difference was observed between the two groups for area under the curve pain scores, with a standardized mean difference (95% CI) of -0.21 cm.h (-0.43 to 0.01; P = 0.058; I2 = 48%). Results were robust to subgroup analysis based on (1) potential conflict of interest and (2) mixing of plain local anesthetics with liposomal bupivacaine. The two groups were not different for any of the day 2 or day 3 secondary outcomes.
CONCLUSIONS: This systematic review and meta-analysis suggests similar analgesic effectiveness between liposomal bupivacaine and plain local anesthetics when used for fascial plane block of the abdominal wall. The authors' analysis does not support an evidence-based preference for liposomal bupivacaine compared to plain local anesthetics for abdominal fascial plane blocks.